What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...
These apps are a breath of fresh air in a world filled with in-app purchases and recurring subscriptions. These are some of my favorite free iPhone apps currently on the market. It turns out that ...
Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail.
(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ongoing IDeate-Lung01 Phase 2 trial shows ifinatamab ...
We note that Merck & Co., Inc. (NYSE:MRK) does have debt on its balance sheet. But the real question is whether this debt is making the company risky. Debt assists a business until the business ...